Cranial neuropathy during severe acute respiratory syndrome coronavirus 2 infection: a case report Authors: Roya Yazdani, Farzaneh Barzkar, Zahra Mirzaasgari Published: 2025 ABSTRACT AbstractBackgroundCranial neuropathy has been reported in association with coronavirus disease 2019. Multiple reports have highlighted the possibility of Miller Fisher syndrome as a delayed immune-mediated response to severe acute respiratory syndrome coronavirus 2 infection. However, cranial neuropathy during the infectious phase of coronavirus disease 2019 with positive cerebrospinal fluid polymerase chain reaction has not been reported to date.Case presentationWe report a 53-year-old Iranian woman who presented with right ptosis, diplopia, and headache without any respiratory symptoms of coronavirus disease 2019. Further evaluations revealed severe acute respiratory syndrome coronavirus(SARS CoV) 2 in the patient’s nasopharyngeal sample and cerebrospinal fluid. The patient’s neurological symptoms improved after treatment with remdesivir and corticosteroids.ConclusionWe suggest that cranial nerve-related symptoms can occur in the context of acute severe acute respiratory syndrome coronavirus 2 infection via direct viral invasion and secondary immune-mediated injury following primary infection. Clinicians should consider coronavirus disease 2019 in patients with symptoms related to cranial nerve involvement, even without systemic or respiratory symptoms of this viral infection.Keywords: Cranial neuropathy, Ptosis, Diplopia, COVID-19, Neurology, Case report Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), has shown strong tropism for the nervous system [1]. Although anosmia and hypogeusia have been recognized as common symptoms of COVID-19 through many potential mechanisms, the involvement of other cranial nerves is much less common [2]. Cranial nerve involvement similar to Miller Fisher syndrome has been reported within days following the respiratory symptoms of COVID-19 [3, 4]. However, the involvement of cranial nerves during the infectious phase of the illness and concurrent isolation of the virus has not been reported. We describe the disease course of a woman who presented with diplopia, right ptosis, and facial hemihyposthesia without any history of recent respiratory illness. SARS-CoV-2 was isolated from her cerebrospinal fluid (CSF) and nasopharyngeal samples. We postulate that direct cranial nerve invasion may have occurred in this patient with COVID-19. Case report A 53-year-old Iranian woman presented to the emergency department with severe (7–8/10 intensity on the visual analog scale) acute generalized headache that started 5 days before presentation and acute onset of horizontal binocular diplopia and right droopy eyelid that had evolved over 2 days. She did not report eye pain or redness, fever, nausea, vomiting, tinnitus, hearing loss, or a history of trauma. The review of systems did not reveal further symptoms. Her past medical history was remarkable for poorly controlled diabetes mellitus for 3 years. She was taking metformin 1000 mg twice daily. During her physical examination, she was awake and alert; her right eyelid was drooping. Vital signs revealed a blood pressure of 130/79 mmHg, heart rate of 89 beats per minute, respiratory rate of 16 breaths per minute, oxygen saturation of 98% on room air, and temperature of 36.6°C. Upon neurologic exam, pupils were equal-sized and reactive to light; there was no relative afferent pupillary defect. Ocular motility examination showed restricted upgaze, adduction, and downgaze of the right eye. Her visual acuity was 5/10 in both eyes (preexisting diabetic retinopathy). Fundus examinations did not show optic nerve abnormalities. Sensory examination of her face revealed impaired pain sensation on the right side of the face involving the ophthalmic, maxillary, and mandibular divisions of the trigeminal nerve. Corneal reflex was symmetrically detected. All facial muscles, including the temporalis and masseters, showed normal (5/5) strength. The remainder of the physical examination was unremarkable. On the basis of the acute onset of headache, the involvement of cranial nerves III and V, and the history of poorly controlled diabetes in this patient, our most probable differential diagnoses included acute ischemic oculomotor nerve palsy, sinus mucormycosis, cavernous sinus thrombosis, meningitis, cerebrovascular aneurysm, brain tumors, and cerebral venous thrombosis with ischemic infarcts. Thus, we ordered further workup, including laboratory testing and imaging: brain computed tomography (CT), brain magnetic resonance imaging (MRI), brain magnetic resonance angiography (MRA), brain magnetic resonance venography (MRV), paranasal sinuses (PNS) CT, and chest CT. The findings of the brain CT and MRI with and without contrast did not show any intracranial lesions suggesting infiltration, mass, or infection. Brain MRA ruled out intracranial aneurysm, and there was no evidence of venous thrombosis in the brain MRV. PNS CT ruled out space-occupying lesions, including infections and tumoral lesions in paranasal sinuses. The laboratory findings did not show any abnormalities. Since the result of the polymerase chain reaction (PCR) of the nasopharyngeal swab sample was positive for coronavirus (SARS-CoV-2), we performed a lumbar puncture with a normal opening pressure. Cerebrospinal fluid (CSF) study showed no white blood cells (WBC); CSF red blood cell(RBC) count equaled 600 cells/mm, protein 79 mg/dL, glucose 113 mg/dL, and lactate dehydrogenase 36 U/ml. Neither Gram stain nor culture showed microorganisms, but the result of CSF PCR (Viga SARS-CoV-2 Molecular Diagnostic Kit; this kit is designed for qualitative diagnostic of RdRP genes and N gene from SARS-COV-2 genome. Cycle threshold: 40) was positive for SARS-CoV-2. Chest CT did not show any evidence of COVID-19 pulmonary involvement. The final diagnosis was SARS-CoV-2 infection of the cranial nerves. The patient was treated for COVID-19 with intravenous remdesivir and dexamethasone for 5 days per hospital protocols at the time of patient admission. Her serum glucose levels were controlled with insulin infusions. Upon discharge, symptoms of ocular motor paresis and right-face hemihyposthesia moderately improved. She did not complain of loss of facial sensation anymore. On the follow-up visit, the patient reported continued improvement of her neurological symptoms after discharge. Discussion COVID-19 affects the nervous system in about 36.4% of patients, causing various symptoms including dizziness, headache, anosmia, hypogeusia, and cerebrovascular events [5]. Anosmia is a particularly frequent presenting symptom that is thought to be mediated by direct invasion of the virus to the olfactory nerve (CN I) and a concomitant inflammation [5]. Involvement of other cranial nerves is less common in the acute phase of COVID-19. It has mostly been reported as Miller Fisher syndrome and other forms of Guillain–Barré syndrome (GBS) following a mild respiratory presentation of COVID-19, and less commonly, as Bell’s syndrome within 9 days of COVID-19 symptom onset [3, 5–7]. A less common presentation of COVID-19-associated cranial neuropathy is isolated cranial neuropathy, which occurs within 5 days of respiratory symptoms [8]. This presentation has been reported in one patient in whom it was associated with concurrent respiratory symptoms and SARS-COV2 positivity of nasopharyngeal specimen. However, the latter patient refused to undergo a lumbar puncture [9]. Our patient was unique because she had isolated cranial neuropathies without associated respiratory symptoms, and the virus was detected concurrently in her nasopharyngeal and cerebrospinal fluid samples. Involvement of cranial nerves with COVID-19 has been reported in patients with Miller Fisher syndrome following SARS-CoV-2 infection, where neurological manifestations were reported to be an aberrant immune response to SARS-CoV-2 [4]. The most commonly affected cranial nerves in patients with COVID-19 include the facial nerve (VII) and the abducens nerve (VI). A systematic review by Tonkal et al. reported that facial nerve impairment occurred in approximately 26% of cases, often presenting as facial paralysis characterized by an inability to close the eye and drooping of the mouth. The abducens nerve was affected in about 12% of cases, leading to symptoms such as diplopia (double vision) due to impaired lateral eye movement. Other cranial nerves, including the trigeminal (V), glossopharyngeal (IX), and vagus (X) nerves, have also shown involvement, contributing to a range of neurological manifestations such as dysphagia and altered taste sensations [10]. It may be argued that the elevated protein levels may point to a diagnosis of GBS in our patient [11]. The mildly elevated CSF protein (79 mg/dL) in our patient is also found in GBS. However, our patient’s symptoms did not match those of Miller Fisher syndrome or other variants of GBS, especially for unilaterality of symptoms, lack of ataxia, spontaneous resolution of symptoms within weeks, and lack of involvement of other muscles. The exact mechanism of neurological involvement in our patient is unclear. In most patients with neurological symptoms associated with COVID-19, the virus cannot be isolated from the CSF, suggesting a different pathophysiological mechanism from other viral infections [12]. Proposed mechanisms may include direct viral injury to the nerves, damage through the systemic inflammatory state, a direct immune response against neurons and glial cells, and microvascular damage [3, 10, 11]. Since our patient suffered from diabetes mellitus, which put her at risk of microvascular disease, her symptoms can also be attributed to the microvascular effects of the virus on preexisting vascular pathology. However, this is less likely given the progressive course of symptoms and the presence of SARS-CoV-2 in the patient’s CSF. Because our patient showed typical symptoms of multiple cranial neuropathies without preceding respiratory symptoms, and with SARS-CoV-2 in her CSF that improved after antiviral treatment, we postulate that the patient’s symptoms can be explained by direct invasion of SARS-CoV-2 to the cranial nerves. However, since COVID-19 is a self-resolving illness in most patients, it is unclear whether our approach to treating the patient was effective. We decided to follow this approach because of hospital protocol and to prevent further neural damage. Moreover, our approach was supported by the other cases as highlighted by the Tonkal systematic review, where a combination of antivirals and steroids was prescribed [9, 10]. Although case reports can never present evidence for the effectiveness of interventions, primarily due to the lack of a control group, their results can be helpful for clinical decision-making for rare diseases. Conclusion This patient presented with isolated cranial neuropathies and headache associated with SARS-COV2 positivity in her nasopharyngeal sample as well as CSF. Though this case report cannot infer a causal relationship, it highlights the possibility of direct viral infection as a mechanism of cranial neuropathy in COVID-19. However, this mechanism cannot be confirmed until it is validated in biopsies and autopsies of cranial nerves in patients with COVID-19. Acknowledgements We would like to thank the patient for agreeing to share her clinical information with the readers of this article. Author contributions R. Yazdani took the patient history and helped gather the data. F. Barzkar drafted the manuscript and searched the literature. Z. Mirzaasgari was the attending physician who diagnosed the patient and contributed to the quality of the paper. Funding We did not receive any funding for this case report. Availability of data and materials The data supporting the findings of this study are available within the article. Declarations Ethics approval and consent to participate This article is based on a case report that is exempt from review by an IRB. The patient provided informed consent for the publication of this case report. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data supporting the findings of this study are available within the article.